Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Advances in Immunology, a long-established and highly respected publication, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for the future.Contributions from leading authoritiesInforms and updates on all the latest developments in the field

Immunoglobulins. --- Antibody diversity. --- Allergy and immunology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.

Biomedicine. --- Pharmaceutical Sciences/Technology. --- Medicine. --- Pharmaceutical technology. --- Médecine --- Techniques pharmaceutiques --- Antibody-drug conjugates. --- Antibody-toxin conjugates. --- Drugs -- Research. --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Conjugates, Antibody-toxin --- Immunoconjugates --- Immunoglobulin-toxin conjugates --- Immunotoxins --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Drugs --- Dosage forms --- Pharmaceutical laboratory techniques --- Pharmaceutical laboratory technology --- Technology, Pharmaceutical --- Technology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume is a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Biomedicine. --- Cancer Research. --- Drug Resistance. --- Pharmacology/Toxicology. --- Medicine. --- Oncology. --- Drug interactions. --- Toxicology. --- Médecine --- Cancérologie --- Médicaments --- Toxicologie --- Interaction --- Medicine --- Health & Biological Sciences --- Oncology --- Antibody-toxin conjugates. --- Cancer --- Treatment. --- Cancer therapy --- Cancer treatment --- Conjugates, Antibody-toxin --- Immunoconjugates --- Immunoglobulin-toxin conjugates --- Immunotoxins --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Therapy --- Cancer research. --- Drug resistance. --- Pharmacology. --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Chemicals --- Pharmacology --- Poisoning --- Poisons --- Interactions, Drug --- Drugs --- Tumors --- Toxicology --- Side effects --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Pharmacy --- Resistance to drugs --- Cancer research --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In his 1962 book "The Structure of Scientific Revolutions", Thomas Kuhn famously argued that researchers in every field of scientific enquiry always operate under a set of presuppositions known as paradigms that are rarely explicitly stated. In the field of HIV vaccine research, several prevailing paradigms led scientists for many years to pursue unfruitful lines of investigations that impeded significant progress. The uncritical acceptance of reigning paradigms makes scientists reluctant to abandon their mistaken assumptions even when they obtain results that are not consistent with the paradigms. The following five paradigms which disregard the degeneracy of the immune system were particularly harmful. 1) There is a primary and intrinsic epitope specific for each B cell receptor and for the corresponding monoclonal antibody. In reality, there is no single, intrinsic or "real" epitope for any antibody but only a diverse group of potential ligands. 2) Reactions with monoclonal antibodies are more specific than the combined reactivity of polyclonal antibodies. In reality, a polyclonal antiserum has greater specificity for a multiepitopic protein because different antibodies in the antiserum recognize separate epitopes on the same protein, giving rise to an additive specificity effect. By focusing vaccine design on single epitope-Mab pairs, the beneficial neutralizing synergy that occurs with polyclonal antibody responses is overlooked. 3) The HIV epitope identified by solving the crystallographic structure of a broadly neutralizing Mab – HIV Env complex should be able, when used as immunogen, to elicit antibodies endowed with the same neutralizing capacity as the Mab. Since every anti HIV bnMab is polyspecific, the single epitope identified in the complex is not necessarily the one that elicited the bnMab. Since hypermutated Mabs used in crystallographic studies differ from their germline-like receptor version present before somatic hypermutation, the identified epitope will not be an effective vaccine immunogen. 4) Effective vaccine immunogenicity can be predicted from the antigenic binding capacity of viral epitopes. Most fragments of a viral antigen can induce antibodies that react with the immunogen, but this is irrelevant for vaccination since these antibodies rarely recognize the cognate, intact antigen and even more rarely neutralize the infectivity of the viral pathogen that harbors the antigen. 5) The rational design of vaccine immunogens using reverse vaccinology is superior to the trial-and-error screening of vaccine candidates able to induce protective immunity. One epitope can be designed to increase its structural complementarity to one particular bnMab, but such antigen design is only masquerading as immunogen design because it is assumed that antigenic reactivity necessarily entails the immunogenic capacity to elicit neutralizing antibodies. When HIV Env epitopes, engineered to react with a bnMab are used to select from human donors rare memory B cells secreting bnAbs, this represents antigen design and not immunogen design. The aim of this Research Topic is to replace previous misleading paradigms by novel ones that better fit our current understanding of immunological specificity and will help HIV vaccine development.

HIV tolerogenic vaccine --- germline antibodies --- SIV vaccine --- Mucosal vaccine --- Therapeutic vaccine --- vaccine efficacy trials --- neutralizing antibodies --- structure-based reverse vaccinology --- antibody polyspecificity --- bacterial adjuvants

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Molecular Biology of B Cells, Second Edition is a comprehensive reference to how B cells are generated, selected, activated and engaged in antibody production. All of these developmental and stimulatory processes are described in molecular, immunological, and genetic terms to give a clear understanding of complex phenotypes. Molecular Biology of B Cells, Second Edition offers an integrated view of all aspects of B cells to produce a normal immune response as a constant, and the molecular basis of numerous diseases due to B cell abnormality. The new edition continues its success with update

Molecular immunology. --- B cells. --- Immunoglobulins. --- Immunoglobulin genes. --- Antibody genes --- Ig genes --- Ir genes --- Antibodies --- Immune globulins --- Immune serum globulin --- Blood proteins --- Globulins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- B lymphocytes --- Bone marrow derived cells --- Bursa equivalent cells --- Antigen presenting cells --- Lymphocytes --- Immune system --- Immunity --- Immunology --- Molecular biology --- Molecular aspects